63695-48-7

Usage

Uses

Used in Pharmaceutical Industry:
2-(4-chlorophenyl)-5-(trifluoromethyl)-2,4-dihydro-3H-pyrazol-3-one is used as a building block or intermediate for the synthesis of various pharmaceuticals. Its potential biological activities and pharmacological properties make it a valuable compound in the development of new drugs for the treatment of various diseases.
Used in Agrochemical Industry:
2-(4-chlorophenyl)-5-(trifluoromethyl)-2,4-dihydro-3H-pyrazol-3-one is also used as a building block or intermediate in the synthesis of agrochemicals. Its potential applications in this industry include the development of new pesticides, herbicides, or other agricultural chemicals to improve crop protection and yield.
Used in Research and Development:
2-(4-chlorophenyl)-5-(trifluoromethyl)-2,4-dihydro-3H-pyrazol-3-one is primarily used in research and development for both medicinal and agricultural purposes. Its potential applications in these fields are being explored to better understand its biological activities and pharmacological properties, with the aim of discovering new treatments and products for various industries.

Upstream product

• 1073-69-4 N-4-chlorophenylhydrazine 
• 372-31-6 ethyl 4,4,4-trifluoroacetoacetate 
• 1073-70-7 4-chlorophenylhydrazine hydrochloride 

Downstream Products

• 1078132-12-3 C₁₇H₉Cl₂F₃N₂O₂ 
• 1384431-71-3 diethyl 1-(4-chlorophenyl)-3-(trifluoromethyl)-1H-furo[2,3-c]pyrazole-4,5-dicarboxylate 
• 1384431-70-2 dimethyl 1-(4-chlorophenyl)-3-(trifluoromethyl)-1H-furo[2,3-c]pyrazole-4,5-dicarboxylate 
• 1384431-59-7 4-diazo-1-(4-chlorophenyl)-3-trifluoromethylpyrazolin-5-one 

Relevant academic research and scientific papers

Novel hybrids of 3-n-butylphthalide and edaravone: Design, synthesis and evaluations as potential anti-ischemic stroke agents

Abstract Fourteen hybrids (10a-g, 11a-g) of 3-n-butylphthalide (NBP) and edaravone (Eda) analogues have been designed and synthesized as potential anti-ischemic stroke agents. In vitro biological studies showed that compounds 10d and 10g exhibited more potent anti-platelet aggregation than ticlopidine (Ticlid), aspirin (ASP) and NBP. Compound 10g more significantly prevented H2O2-mediated neuronal cell (PC12) death than NBP, Eda or NBP together with Eda. Meanwhile, 10g also possessed potent radical scavenging effects on hydroxyl radical (·OH) and superoxide anion radical (·O2-). Our findings may provide new insights into the development of these hybrids, like 10g, for the intervention of ischemic stroke.

Synthesis, biological evaluation and SAR study of novel pyrazole analogues as inhibitors of Mycobacterium tuberculosis

As a continuation of our previous work that turned toward the identification of antimycobacterial compounds with innovative structures, two series of pyrazole derivatives were synthesized by parallel solution-phase synthesis and were assayed as inhibitors of Mycobacterium tuberculosis (MTB), which is the causative agent of tuberculosis. One of these compounds showed high activity against MTB (MIC = 4 μg/mL). The newly synthesized pyrazoles were also computationally investigated to analyze their fit properties to the pharmacophoric model for antitubercular compounds previously built by us and to refine structure-activity relationship analysis.

2-(pyrazol-5-yl-oxymethyl)-1,2-benzisothiazol-3 (2H)-One 1, 1-dioxides and compositions and method of use thereof

2-(Pyrazol-5-yl-oxymethyl)-1,2-benzisothiazol-3(2H)-one 1,1-dioxides, pharmaceutical compositions containing them and methods for the treatment of degenerative diseases utilizing them.